Literature DB >> 28633333

Anti-natural octyl disaccharide-leprosy IDRI diagnostic (NDO-LID) antibodies as indicators of leprosy reactions and neuritis.

Héctor Serrano-Coll1, Mónica Muñoz1, Juan Camilo Beltrán1, Malcolm S Duthie2, Nora Cardona-Castro1,3.   

Abstract

Background: Leprosy is a complex infectious and neurological disease caused by Mycobacterium leprae. Nerve damage is related to immunological hypersensitivity responses known as leprosy reactions (LRs). Diagnostic tools to predict LRs are not available. We hypothesized that natural octyl disaccharide-leprosy IDRI diagnostic (NDO-LID) would be helpful as an indicator of LRs and neuritis.
Methods: To assess the utility of NDO-LID in indicating reactions, ELISA were used to detect specific antibodies in serum samples from 80 Colombian leprosy patients (40 with and 40 without history of LRs). Responses were detected using a range of detection reagents detecting IgG, IgM or both isotypes.
Results: Patients with a history of LRs had an increased seropositivity rate for anti-NDO-LID antibodies compared to patients without (anti-NDO-LID protein A [p=0.02], IgG anti-NDO-LID [p=0.01] and IgM anti-NDO-LID [p=0.01]). Further analyses of patients with a history of LRs indicated that both seropositivity rate and magnitude of responses were elevated among patients with neuritis versus those without neuritis (anti-NDO-LID protein A [p=0.03], IgG anti-NDO-LID [p=0.001] and IgM anti-NDO-LID [p=0.06]). Conclusions: Our data indicate that testing for serum anti-NDO-LID antibodies can be a useful screen to identify patients at risk of developing LRs and neuritis.
© The Author 2017. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibodies; Biomarkers; Leprosy reactions; Mycobacterium leprae; Neuritis; Serology

Mesh:

Substances:

Year:  2017        PMID: 28633333     DOI: 10.1093/trstmh/trx026

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  5 in total

1.  Social and environmental conditions related to Mycobacterium leprae infection in children and adolescents from three leprosy endemic regions of Colombia.

Authors:  Héctor Serrano-Coll; Hugo Rene Mora; Juan Camilo Beltrán; Malcolm S Duthie; Nora Cardona-Castro
Journal:  BMC Infect Dis       Date:  2019-06-13       Impact factor: 3.090

Review 2.  The immunology of other mycobacteria: M. ulcerans, M. leprae.

Authors:  Katharina Röltgen; Gerd Pluschke; John Stewart Spencer; Patrick Joseph Brennan; Charlotte Avanzi
Journal:  Semin Immunopathol       Date:  2020-02-25       Impact factor: 9.623

3.  Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.

Authors:  Emerith M Hungria; Samira Bührer-Sékula; Regiane M Oliveira; Lúcio C Aderaldo; Maria Araci A Pontes; Rossilene Cruz; Heitor S de Gonçalves; Maria L F Penna; Gerson O Penna; Mariane M A Stefani
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

4.  Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.

Authors:  Francianne M Amorim; Maurício L Nobre; Larissa S Nascimento; Alesson M Miranda; Glória R G Monteiro; Francisco P Freire-Neto; Maria do Carmo Palmeira Queiroz; José W Queiroz; Malcolm S Duthie; Marcos R Costa; Steven G Reed; Warren D Johnson; Kathryn M Dupnik; Selma M B Jeronimo
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28

5.  Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China.

Authors:  Liu Jian; Shang Xiujian; You Yuangang; Xing Yan; Yuan Lianchao; Malcolm S Duthie; Wen Yan
Journal:  Trans R Soc Trop Med Hyg       Date:  2020-02-07       Impact factor: 2.184

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.